Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
Medtronic is setting up a de facto incubator in Singapore, planning to design, test and scale new business models for the developing world.
It apparently was not enough that the owner of a company that makes the active pharmaceutical ingredients for a couple of Pharmstandard's key OTC products is a member of its board; Pharmstandard said today it will pay him nearly $600 million for his company to secure a long-term supply of the ingredients.
Despite slumping royalty revenue, Singapore's Biosensors is counting on new products and recent acquisitions to carry it to 15% growth in fiscal 2014, expecting more than $386 million for the year.
Merck has been cutting manufacturing operations around the globe in the face of challenged earnings but continues to expand in China 20 years after erecting its first manufacturing facility there.
The two groups have been working together for the past decade, helping build the city-state's reputation for R&D.
Researchers in Singapore and colleagues across Asia made two major advances in lymphoma diagnostics that offers both bad and good news.
Pfizer is dumping its clinical research operation in Singapore, part of an effort to cut about $1.3 billion from its R&D budget, and the divestiture could mean more opportunity for outsourcers looking to partner with the drug giant.
As Pfizer continues to cut costs, it has just taken the ax to a clinical research facility in a market where others are beefing up, Singapore.
As the drug giant seeks to carve out more than $1 billion for its budget, Pfizer confirmed plans to exit a clinical research operation in Singapore.